相关临床试验
150
16 进行中
药物批准
342
批准总数
监管机构
6
监管机构数
成立时间
N/A
进行中（未招募）
15
10.0%
已完成
103
68.7%
尚未招募
1
0.7%
招募中
2
1.3%
终止
18
12.0%
Unknown
2
1.3%
撤回
9
6.0%
- Heron Therapeutics reported Q1 2026 total net revenue of $34.7 million, down 10.8% year-over-year, despite strong 32% growth in its Acute Care franchise. - ZYNRELEF and APONVIE demonstrated robust performance with 27% and 50% revenue growth respectively, while the Oncology franchise declined 26.3% primarily due to SUSTOL wind-down. - The company reaffirmed its 2026 full-year guidance of $173-$183 million net revenue and $10-$20 million Adjusted EBITDA despite posting a Q1 net loss of $8.1 million. - Heron reached a settlement with Baxter Healthcare Corporation in CINVANTI patent litigation and continues advancing its ZYNRELEF prefilled syringe program with 12-month stability data expected in Q1 2027.
- Spectral Medical and Baxter Healthcare Corporation have extended their exclusive supply and distribution agreement for PMX, a therapy for septic shock, by 10 years post-FDA approval. - The agreement ensures Baxter remains Spectral's exclusive partner for distributing PMX products in the U.S. and Canada, pending FDA approval, enhancing commercialization prospects. - Baxter's commitment includes a milestone payment to Spectral following the enrollment of 90 patients in the PMX-focused Tigris Trial, highlighting support for PMX's clinical development. - The Tigris Trial, a confirmatory study of PMX, is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics to evaluate PMX's efficacy in endotoxic septic shock.
